XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborative Arrangements - Schedule of Transactions (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 11,402 $ 9,353 $ 22,029 $ 19,641  
Cost of sales 3,104 2,747 6,303 5,576  
Selling, general and administrative 2,281 2,085 4,468 4,276  
Research and development 4,321 2,085 6,732 4,260  
Payables, current 21,906   21,906   $ 27,327
Other current assets | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from Bayer included in Other current assets 258   258   215
Other current assets | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from Bayer included in Other current assets 212   212   157
Other current assets | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables from Bayer included in Other current assets 65   65   65
Accounts payable and accrued liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, current 418   418   423
Accounts payable and accrued liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, current 600   600   335
Other Noncurrent Liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to Bayer included in Other Noncurrent Liabilities 0   0   600
Other Noncurrent Liabilities | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables to Bayer included in Other Noncurrent Liabilities 400   400   $ 0
Revenue | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 256 178 489 323  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza (1)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 248 178 475 323  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 8 0 14 0  
Revenue | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 181 151 310 279  
Revenue | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 74 79 149 133  
Sales 149 136 279 246  
Revenue | Bayer AG | Collaborative Arrangement | Adempas          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative Arrangement, Sales, Net 74 57 129 113  
Revenue | Bayer AG | Collaborative Arrangement | Verquvo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative Arrangement, Sales, Net 1 0 1 0  
Cost of sales | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 42 137 84 164  
Cost of sales | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 47 135 94 170  
Cost of sales | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 39 28 229 57  
Amortization of intangible assets 153        
Selling, general and administrative | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 43 39 83 72  
Selling, general and administrative | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 31 19 54 31  
Selling, general and administrative | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 32 17 58 28  
Research and development | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 31 37 60 73  
Research and development | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 57 56 121 120  
Research and development | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development $ 13 $ 16 $ 20 $ 41